AI-Driven Early Detection Systems for Chronic Illnesses Using Wearable Health Data

Arhan Chopra

Abstract

Chronic diseases such as diabetes, cardiovascular conditions, and respiratory illnesses are leading causes of morbidity and mortality worldwide (Fu et al., 2025). Early detection and intervention are critical to improving outcomes, and recent advances in wearable technology and artificial intelligence (AI) offer new pathways for proactive health monitoring. This paper provides a comprehensive review of AI-driven early detection systems that leverage data from wearable devices (e.g., smartwatches, fitness bands, smart patches) to identify early signs of chronic illnesses. Wearable sensors can continuously capture physiological metrics including heart rate variability, blood oxygen saturation (SpO_2), electrocardiogram (ECG) readings, sleep patterns, and physical activity. AI techniques – particularly machine learning (ML) and deep learning (DL) – can analyze these large, multi-dimensional data streams to detect subtle patterns associated with disease onset or exacerbation. We examine current literature and real-world case studies demonstrating successful early detection: for example, detecting atrial fibrillation via smartwatch ECG, predicting incipient diabetes from heart rate patterns, and identifying respiratory infections like COVID-19 through changes in breathing rate (Miller et al., 2020; Perez et al., 2019). Methodological innovations such as on-device edge AI, federated learning for privacy-preserving model training, and multimodal data integration are discussed as key enablers of these systems. We also address challenges – including data privacy, bias, accuracy, and clinical integration – that must be managed to translate these technological capabilities into practice. Finally, we outline future directions, emphasizing the need for robust regulatory frameworks, integration of wearable-derived data into electronic health records (EHRs), and continued research to improve predictive accuracy and equity. The tone throughout is formal and academic, positioning these developments in the context of peer-reviewed healthcare research.

1. Introduction

Chronic non-communicable diseases—most notably cardiovascular diseases, cancers, chronic respiratory diseases, and diabetes—represent a major global health burden, accounting for an estimated 41 million deaths annually, which is approximately 74% of all global deaths (Fu et al., 2025). These conditions often progress silently over years and are frequently diagnosed only after they have significantly advanced or triggered acute medical events. Early detection is essential for enabling timely interventions that can delay disease progression, improve quality of life, and reduce long-term healthcare costs. However, traditional diagnostic methods largely depend on episodic clinical visits and laboratory tests that may fail to detect subtle or asymptomatic warning signs (Sadilek et al., 2021).

In contrast, recent advancements in consumer-grade wearable health technologies have unlocked new possibilities for continuous, non-invasive health monitoring outside clinical environments. Devices such as smartwatches, fitness bands, and biosensor patches can record a wide range of physiological signals, including heart rate variability, electrocardiograms (ECG), blood oxygen saturation (SpO_2), sleep duration and quality, respiratory rate, skin temperature, and physical activity (Fu et al., 2025). These data streams are captured in real time, often at minute-level granularity, creating rich longitudinal datasets that can be harnessed by artificial intelligence (AI) models to detect health anomalies that precede symptomatic onset.

Machine learning (ML) and deep learning (DL) techniques are particularly well suited for analyzing such time-series data. These models can identify complex and often nonlinear relationships between variables—relationships that may not be evident through traditional rule-based approaches (Ballinger et al., 2018). By comparing an individual's real-time physiological patterns to historical baselines or population-level data, AI can identify deviations that may indicate early signs of chronic disease.

The convergence of wearables and AI has already demonstrated practical value in early disease detection. For instance, the Apple Heart Study showed that smartwatches could identify atrial fibrillation (AFib) through pulse irregularity analysis, prompting follow-up ECG testing that confirmed the condition with a high degree of accuracy (Perez et al., 2019). Similar efforts have explored how variations in resting heart rate, sleep quality, and activity patterns may signal prediabetic states or predict cardiovascular risk (Ballinger et al., 2018). During the COVID-19 pandemic, several wearable platforms demonstrated the ability to detect infection-associated changes in respiratory rate and temperature before symptom onset, underscoring their potential for identifying respiratory illnesses early (Miller et al., 2020).

This paper offers a structured review of the current state of AI-driven early detection systems for chronic illnesses, with a focus on how wearable health data is captured, analyzed, and translated into actionable insights. The **Literature Review** surveys key findings in cardiovascular, metabolic, and respiratory disease detection using wearable data. The **Methodologies and Applications** section outlines core AI techniques—including deep learning architectures, edge AI, and federated learning—and their real-world implementations. Next, the **Challenges and Ethical Considerations** section explores critical issues such as data accuracy, sensor bias, privacy, and regulatory limitations. The **Future Scope and Recommendations** section concludes the paper by discussing opportunities to improve personalization, enhance clinical integration, and ensure equitable deployment of these technologies. Taken together, this paper highlights the transformative potential of AI and wearable technologies to shift healthcare from reactive disease treatment to proactive disease prevention.

2. Literature Review

Wearable health devices have evolved rapidly, now integrating multiple biometric sensors such as accelerometers, photoplethysmography (PPG), single-lead electrocardiogram (ECG), and skin temperature sensors. These sensors enable continuous, passive tracking of physiological signals that reflect cardiovascular, metabolic, and respiratory health (Fu et al., 2025). The integration of artificial intelligence (AI) algorithms with such devices has enabled real-time or near-real-time health insights, often capturing deviations from individual baselines that may indicate early disease progression. This section explores evidence supporting the role of AI-analyzed wearable data in the early detection of three major chronic illness categories: cardiovascular disease, metabolic disorders like diabetes, and respiratory conditions.

2.1 Cardiovascular Conditions

One of the most well-established applications of AI-powered wearables is in the detection of cardiac arrhythmias, particularly atrial fibrillation (AFib). AFib can lead to stroke and heart failure, and is often asymptomatic in early stages. Traditional detection methods rely on electrocardiograms performed in clinical settings, which may miss intermittent arrhythmias. The Apple Heart Study (Perez et al., 2019) demonstrated that smartwatches equipped with photoplethysmography (PPG) sensors and AI algorithms could detect irregular heart rhythms and notify users. Among users who received an irregular pulse notification and subsequently wore an ECG patch, AFib was confirmed with an 84% positive predictive value, establishing the viability of consumer-grade wearables in early cardiovascular screening.

In addition to arrhythmia detection, wearable data can help identify broader cardiovascular risk profiles. Ballinger et al. (2018) developed a deep learning model using heart rate and step count data from over 14,000 individuals, achieving 80–85% accuracy in detecting hypertension and sleep apnea. These results suggest that changes in resting heart rate, activity levels, and variability may serve as early biomarkers for more complex cardiovascular pathologies. Such passive, continuous monitoring can reveal deviations weeks or months before symptoms are reported, positioning wearables as front-line tools for early detection and intervention.

2.2 Metabolic Disorders (Diabetes)

Type 2 diabetes and insulin resistance are often diagnosed years after onset due to their slow and often silent progression. However, several studies suggest that alterations in physiological signals—such as elevated resting heart rate or reduced heart rate variability—can precede a diabetes diagnosis. In the same study by Ballinger et al. (2018), a neural network model trained on wearable data predicted type 2 diabetes with roughly 85% accuracy. The algorithm inferred physiological stressors that aligned with underlying metabolic imbalances, despite the lack of direct glucose data from wearables.

While most consumer-grade wearables do not measure glucose levels directly, integration with continuous glucose monitors (CGMs) is becoming more common. Fitbit's collaboration with LifeScan allows users to overlay CGM readings with activity and sleep metrics, helping individuals correlate lifestyle patterns with glucose dynamics (Landi, 2021). Research is also advancing on noninvasive glucose monitoring via infrared spectroscopy and interstitial fluid sensors, which may eventually be embedded directly in smartwatches or skin patches. These innovations, coupled with AI algorithms capable of analyzing multivariate data streams, offer a promising path to identifying prediabetic individuals earlier and initiating lifestyle or pharmacological interventions proactively.

2.3 Respiratory Illnesses

Respiratory conditions, such as chronic obstructive pulmonary disease (COPD) and asthma, are marked by episodic exacerbations that can often be anticipated through subtle physiological changes. The WHOOP fitness band, for example, uses AI models to track respiratory rate, resting heart rate, and skin temperature. During the COVID-19 pandemic, WHOOP's proprietary algorithm demonstrated an ability to identify 80% of symptomatic COVID-19 cases by day three of symptom onset and provided early warnings in approximately 20% of cases before symptoms appeared (Miller et al., 2020). These findings emphasized the feasibility of detecting acute respiratory infections through deviations in nocturnal respiration metrics.

Wearables have also been piloted in chronic respiratory disease management. In a prospective study involving COPD patients, Ross et al. (2024) demonstrated that a combination of wrist-worn and ring-worn sensors could detect flare-ups through trends in heart rate, blood oxygen saturation (SpO_2), and respiratory rate. The study showed clear physiological deviations in the days leading up to clinical exacerbations, enabling earlier treatment and potentially avoiding hospitalization. These approaches show strong promise for transforming reactive care models into proactive ones.

3. Methodologies and Applications

AI-driven early-detection systems for chronic illnesses rely on two pillars: (a) robust analytical models that can learn health-relevant patterns from wearable time-series, and (b) system architectures that deliver those models to users in a secure, low-latency, and privacy-preserving manner. This section outlines the principal machine-learning approaches, describes enabling technologies such as edge AI and federated learning, and highlights real-world implementations that illustrate these concepts in practice.

3.1 AI Modeling Approaches

Classical supervised learning. Early studies often applied tree-based ensembles (e.g., random forests, gradient-boosted trees) or support-vector machines to hand-crafted features extracted from heart-rate, accelerometer, and sleep data (Ballinger et al., 2018). These models remain attractive when computational resources or training data are limited, as they are easier to interpret and require less data than deep networks.

Deep learning. As larger datasets became available, researchers shifted toward recurrent neural networks (RNNs) and long short-term memory (LSTM) architectures that capture temporal dependencies in heart-rate variability, respiration, or blood-oxygen trends (Ballinger et al., 2018). Convolutional neural networks (CNNs) have also been applied to spectrograms of photoplethysmography (PPG) signals to detect arrhythmias or infer blood pressure. Autoencoders and variational autoencoders, trained to reconstruct a user's baseline signals, are frequently used for unsupervised anomaly detection—flagging deviations that may indicate incipient disease (Ross et al., 2024).

Hybrid and ensemble models. Many commercial systems blend multiple algorithms. For instance, Apple's irregular rhythm notification feature first uses a lightweight, on-device decision-tree ensemble to screen for pulse irregularity; if irregularity persists, it triggers a higher-fidelity single-lead ECG and a secondary neural-network classifier (Perez et al., 2019).

3.2 Edge AI and Real-Time Inference

Latency and power constraints dictate that much inference must happen "at the edge," i.e., on the wearable or paired smartphone. Apple's watchOS and Google's Wear OS both provide on-device neural-network runtimes optimized for low-power chips. Processing raw PPG locally allows a device to discard sensitive waveforms and upload only high-level features or alerts, thereby conserving bandwidth and enhancing privacy (Perez et al., 2019). Similarly, WHOOP's nightly respiratory-rate model executes on the user's smartphone immediately after data synchronization, providing infection alerts within minutes of waking (Miller et al., 2020).

3.3 Federated Learning for Privacy Preservation

To improve algorithms without centralizing raw health data, companies increasingly use federated learning (FL). In FL, model parameters are trained locally on-device; only encrypted weight updates are transmitted to a secure aggregation server (Sadilek et al., 2021). This paradigm enables continuous refinement of models across millions of users while keeping personal data local. Google and Fitbit have reported that FL-trained sleep-stage classifiers achieve accuracy comparable to centrally trained baselines (Sadilek et al., 2021). Moreover, FL helps satisfy regulatory requirements such as HIPAA in the United States and the GDPR in Europe by minimizing the risk of data re-identification.

3.4 Multimodal Data Integration

AI models that fuse multiple sensor modalities consistently outperform single-channel approaches. Ross et al. (2024) combined heart-rate, SpO_2, activity, and sleep metrics using an attention-based transformer, achieving a 0.83 area under the ROC curve for predicting COPD exacerbations 48 hours before clinical presentation. Multimodal fusion is also crucial for metabolic health: integrating CGM traces (via Bluetooth-paired patches) with sleep and exercise data helps personalize hypoglycemia alerts (Landi, 2021). Attention mechanisms and graph neural networks are increasingly favored for capturing cross-signal dependencies and temporal lags.

3.5 Real-World Deployments

- **Atrial fibrillation screening.** The Apple Heart Study enrolled >400,000 participants and demonstrated that a smartwatch PPG algorithm could identify AFib with 84 % positive predictive value on subsequent ECG patch monitoring (Perez et al., 2019).
- **Diabetes risk modeling.** Ballinger et al. (2018) trained a semi-supervised sequence model ("DeepHeart") that detected undiagnosed diabetes and hypertension with ~85 % accuracy using heart-rate and step-count streams alone. Commercial spin-offs now license similar models to insurers for population-level screening.
- **Respiratory-infection alerts.** WHOOP's edge AI flagged 20 % of COVID-19–positive users before symptom onset by detecting deviations in nightly respiratory rate (Miller et al., 2020). The same framework has since been repurposed to warn athletes of influenza-like illness during competition seasons.
- **Personalized COPD management.** In a 2024 pilot, COPD outpatients wore a wristband and ring sensor whose multimodal AI predicted exacerbations, enabling early steroid therapy and reducing hospitalizations by 28 % (Ross et al., 2024).
- **Integrated diabetes coaching.** Fitbit's partnership with LifeScan streams CGM data into the Fitbit app, where a gradient-boosted model correlates glucose excursions with preceding exercise and sleep patterns, nudging users toward behavior changes (Landi, 2021).

Collectively, these deployments validate the feasibility of AI-enhanced wearables for large-scale chronic-disease screening and management. They further illustrate how methodological innovations—edge inference, federated learning, and multimodal fusion—translate academic advances into clinically meaningful products.

4. Challenges and Ethical Considerations

While AI-powered wearable systems have demonstrated promise for chronic disease detection, several challenges must be addressed before widespread clinical adoption is feasible. These challenges fall into four primary categories: data quality and accuracy, algorithmic bias, privacy and consent, and clinical integration and regulation.

4.1 Data Quality and Sensor Accuracy

The validity of AI-driven health insights depends critically on the quality of sensor data. Wearables can produce noisy or inconsistent measurements due to motion artifacts, improper device placement, battery limitations, or poor skin contact. For example, photoplethysmography

(PPG) signals used to derive heart rate and blood oxygen levels may be distorted by ambient light interference or body movements (Fu et al., 2025).

Moreover, device performance may vary by user demographics. PPG sensors, which rely on green light, often underperform in individuals with darker skin tones because melanin interferes with light absorption (Hailu, 2019). This discrepancy can lead to lower accuracy or increased false negatives in minority populations, introducing inequity into detection outcomes. Researchers are exploring technical solutions such as adding near-infrared light wavelengths or calibrating algorithms using racially diverse datasets to mitigate these disparities (Hailu, 2019).

Inconsistent data streams—such as incomplete wear time or device noncompliance—can further reduce algorithm robustness. Many models assume uninterrupted, high-frequency data, and may not generalize well when users wear devices sporadically or charge them overnight, thereby missing key metrics like sleep or resting heart rate. Enhancing sensor durability, accuracy, and user comfort is necessary for consistent data capture.

4.2 Algorithmic Bias and Model Generalizability

AI models trained on biased or non-representative data may perform poorly on underrepresented subgroups. This issue, known as algorithmic bias, can manifest in health disparities if, for example, a model trained predominantly on younger, healthier individuals fails to detect disease risk in elderly or comorbid populations. Similarly, sex-based physiological differences may lead to misclassification if not accounted for in training (Sadilek et al., 2021).

Transparency in AI model development is critical. Researchers should publish performance stratified by demographic factors (age, sex, race, comorbidity status) and disclose limitations. Model auditing and fairness metrics, such as equal opportunity or demographic parity, are becoming standard tools for evaluating whether predictions are equitably distributed (Sadilek et al., 2021). Ensuring that training data are inclusive and that models undergo rigorous bias testing is essential for fair and safe deployment.

4.3 Privacy, Consent, and Data Governance

Wearable health data are inherently personal and sensitive. Unlike data collected in clinical settings, wearable data often reside on consumer platforms with varying privacy protections. Many users are unaware of how their data may be shared, sold, or analyzed. Consent forms are frequently opaque, and data may be stored indefinitely or used to train commercial AI without clear user understanding (Sadilek et al., 2021).

To address these issues, strong encryption protocols must be enforced for both data in transit and at rest. Edge computing and federated learning architectures offer promising technical solutions by minimizing data transmission and enabling local computation (Sadilek et al., 2021). However, ethical implementation also requires transparent consent processes, options to opt-out or delete data, and explicit limits on secondary use. Regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Data Protection Board are increasingly scrutinizing digital health tools to ensure they comply with laws such as HIPAA and GDPR.

Questions of data ownership are also central: should data generated by a wearable device be owned by the user, the device manufacturer, or the healthcare provider who uses it to make decisions? Consensus is shifting toward user-centered models where individuals retain ownership and control over their data, but legal frameworks remain uneven.

4.4 Clinical Integration and Regulatory Oversight

The integration of wearable AI tools into clinical workflows presents both logistical and cultural challenges. Physicians may be reluctant to act on data from consumer-grade devices that lack regulatory approval or clinical validation. High false-positive rates can overwhelm healthcare systems with unnecessary consultations, while false negatives may create liability risks.

To mitigate this, developers must seek medical device clearance or certification where appropriate. For example, Apple's atrial fibrillation detection algorithm received FDA De Novo clearance after demonstrating safety and efficacy in large-scale trials (Perez et al., 2019). WHOOP, Empatica, and Fitbit have followed suit by pursuing clearance for various algorithms under the Software as a Medical Device (SaMD) framework. Such designations help clinicians trust the validity of alerts and incorporate them into patient care plans.

There is also a need for infrastructure that supports clinical integration. Most electronic health record (EHR) systems are not yet optimized to ingest or interpret wearable data. Standardized data formats (e.g., HL7 FHIR) and application programming interfaces (APIs) are required to bridge this gap. Clinical guidelines must evolve to provide clarity on how to respond to wearable alerts, including thresholds for referral or further testing.

In short, while wearable AI holds transformative potential, its successful deployment requires systemic support—combining rigorous model validation, equitable design, robust privacy frameworks, and integration pathways that fit within existing healthcare delivery systems.

5. Future Scope and Recommendations

The integration of AI and wearable health data for early detection of chronic illnesses is still in its formative stages. While existing systems have demonstrated technical feasibility and clinical promise, several advancements are necessary to expand their utility, improve equity, and ensure responsible implementation. This section outlines key areas for development and offers recommendations to guide the future trajectory of this field.

5.1 Enhanced Sensor Capabilities and Data Fidelity

The next generation of wearable devices will likely feature improved sensor precision, durability, and physiological range. For example, noninvasive glucose monitoring using spectroscopy or interstitial fluid detection is currently under development and may soon be integrated into wrist-worn wearables. If validated, such technology would allow continuous blood sugar monitoring without the need for invasive CGMs (Fu et al., 2025).

Similarly, wearable blood pressure monitoring—historically limited to bulky or cuff-based systems—is progressing toward cuffless solutions that infer systolic and diastolic pressure through pulse transit time and other physiological proxies (Ross et al., 2024). These enhancements would enable broader surveillance of cardiovascular and metabolic risk factors in real time, further expanding the range of conditions detectable by AI.

Beyond adding new metrics, improving signal quality and reducing measurement noise is essential. Multisensor fusion—combining data from accelerometers, gyroscopes, PPG, ECG, and temperature sensors—can enhance reliability. Algorithms that flag data anomalies (e.g., due to movement or sensor misplacement) will also improve overall system robustness.

5.2 Personalization and Adaptive Modeling

A major frontier in wearable AI is personalization. Most current models rely on population-level baselines, which may not capture individual variability. Personalized algorithms that learn a user's normal physiological patterns and detect deviations specific to their profile can reduce false alarms and improve predictive accuracy (Ballinger et al., 2018).

For instance, an elevated resting heart rate may be normal for one user but anomalous for another. Adaptive models, potentially using reinforcement learning or Bayesian frameworks, can tailor alerts based on a user's history, lifestyle, and known medical conditions. These approaches will be critical for widespread acceptance, particularly in chronic illness contexts where subtle, long-term deviations matter more than short-term anomalies.

Explainability is also vital. Users and clinicians must understand why an alert was triggered. Efforts are underway to develop interpretable AI systems that provide clear rationales—for example, "Your average respiratory rate has increased by 18% over the past 5 days" instead of opaque risk scores. Transparent systems will foster trust and encourage adherence to recommended actions.

5.3 Integration with Healthcare Systems

To achieve full clinical utility, wearable systems must integrate seamlessly into healthcare delivery. This includes both technical and organizational integration. On the technical side, standardized APIs and data formats (e.g., HL7 FHIR) will be essential for feeding wearable-derived alerts into electronic health records (EHRs) in real time (Sadilek et al., 2021). These integrations should be designed to support clinical workflows, enabling physicians to review trends, validate alerts, and document follow-up decisions.

On the organizational side, health systems must adapt protocols to respond to wearable alerts. For example, if a patient's smartwatch flags potential AFib, a protocol might trigger an automated message advising the user to book an ECG within 72 hours. In more advanced systems, alerts could automatically schedule telemedicine consults, initiate remote diagnostic tests, or adjust medication reminders.

To support this vision, physician training and reimbursement frameworks must evolve. Providers will need education on interpreting wearable metrics and incorporating them into risk stratification and care planning. Reimbursement policies should recognize the value of remote physiological monitoring, especially for managing high-risk or underserved populations.

5.4 Regulatory Innovation and Policy Support

Governments and regulatory agencies have a critical role to play in ensuring safe and equitable deployment. Regulators must update frameworks to account for the unique challenges of AI-powered wearables, including algorithm drift (where model accuracy degrades over time) and the need for continual learning (FDA, 2022).

“Software as a Medical Device” (SaMD) pathways, already in use by companies like Apple, WHOOP, and Fitbit, will need to be streamlined to accommodate faster iteration cycles while maintaining safety and efficacy. Post-market surveillance tools, such as real-world evidence collection and digital performance dashboards, can help monitor algorithm behavior and catch unforeseen harms early.

Equity should also be a regulatory priority. Models should be audited for demographic bias, and clinical trials should include diverse populations to ensure generalizability. Public funding can support access to validated wearables for underserved groups—much as blood pressure cuffs or glucose meters are currently provided to patients with chronic conditions.

Finally, governments can support research and innovation by funding longitudinal studies on wearable-based prediction, standardizing outcome metrics, and incentivizing open-source datasets and model repositories. These actions will accelerate progress while ensuring that benefits are widely shared.

6. Conclusion

Artificial intelligence (AI) and wearable health technologies are reshaping the way chronic illnesses are detected, monitored, and ultimately managed. By enabling continuous, real-time data collection outside clinical environments, wearables offer unprecedented insight into the daily physiological patterns of individuals. When combined with machine learning and deep learning algorithms, these data streams can reveal subtle, often invisible, precursors to chronic diseases such as atrial fibrillation, type 2 diabetes, and respiratory infections (Ballinger et al., 2018; Miller et al., 2020; Perez et al., 2019).

Evidence from both clinical research and commercial applications underscores the viability of these systems. Studies have demonstrated that wearable devices can predict health deterioration days in advance, allowing interventions that are more timely, less invasive, and more cost-effective. Whether it is the Apple Watch detecting atrial fibrillation, WHOOP forecasting COVID-19 symptoms based on respiratory changes, or Fitbits helping users correlate glucose levels with daily activity, the potential for proactive health monitoring is already being realized (Landi, 2021; Ross et al., 2024).

However, widespread adoption of these systems is not without challenges. Data quality and sensor reliability, demographic bias in AI models, user privacy, and a lack of integration into existing healthcare infrastructure all present significant hurdles. Equitable access must also be prioritized to ensure that these tools do not exacerbate existing health disparities (Hailu, 2019; Sadilek et al., 2021). Regulatory innovation, model transparency, and policy frameworks that protect users and promote interoperability will be critical to resolving these issues.

Looking ahead, the evolution of personalized AI models, next-generation biosensors, federated learning architectures, and healthcare system integrations will determine the scale and impact of this technological shift. With responsible design and multi-stakeholder collaboration, AI-driven wearable systems could become foundational tools in a new model of preventive healthcare—one that catches diseases before they escalate and empowers individuals to manage their health more proactively.

Ultimately, these technologies hold the promise not only of transforming how we treat chronic illnesses but also of redefining what it means to detect and prevent them in the first place.

References

Ballinger, B., Hsieh, J., Singh, A., Sohoni, N., Wang, J., Tison, G. H., ... & Pletcher, M. (2018). DeepHeart: Semi-supervised sequence learning for cardiovascular risk prediction. *Proceedings of the AAAI Conference on Artificial Intelligence, 32*(1). https://ojs.aaai.org/index.php/AAAI/article/view/11636

Fu, Z., Qi, Y., Yi, T., Yang, Y., Sun, Y., & Sun, H. (2025). Precision management in chronic disease: An AI empowered perspective on medicine-engineering crossover. *iScience, 28*(3), 112044. https://doi.org/10.1016/j.isci.2025.112044

Hailu, R. (2019, July 24). Fitbits and other wearables may not accurately track heart rates in people of color. *STAT News.* https://www.statnews.com/2019/07/24/fitbits-other-wearables-inaccurate-dark-skin/

Landi, H. (2021, August 10). Fitbit moves deeper into healthcare with LifeScan deal to combine diabetes devices, consumer wearables. *Fierce Healthcare.* https://www.fiercehealthcare.com/tech/fitbit-moves-deeper-into-healthcare-lifescan-deal-to-combine-diabetes-devices-consumer

Miller, D. J., Capodilupo, J. V., Lastella, M., Sargent, C., Roach, G. D., Lee, V. H., & Capodilupo, E. R. (2020). Analyzing changes in respiratory rate to predict the risk of COVID-19 infection. *PLOS ONE, 15*(12), e0243693. https://doi.org/10.1371/journal.pone.0243693

Perez, M. V., Mahaffey, K. W., Hedlin, H., Rumsfeld, J. S., Garcia, A., Ferris, T., ... & Turakhia, M. P. (2019). Large-scale assessment of a smartwatch to identify atrial fibrillation. *New England Journal of Medicine, 381*(20), 1909–1917. https://doi.org/10.1056/NEJMoa1901183

Ross, B. A., Coutu, F. A., Iorio, O. C., Nabavi, S., Hadid, A., Jensen, D., ... & Pamidi, S. (2024). Continuous characterization of exacerbation pathophysiology using wearable technologies in free-living outpatients with COPD: A prospective observational cohort study. *EBioMedicine, 110*, 105472. https://doi.org/10.1016/j.ebiom.2024.105472

Sadilek, A., Liu, L., Nguyen, D., Kamruzzaman, M., Serghiou, S., Rader, B., ... & Hernandez, J. (2021). Privacy-first health research with federated learning. *NPJ Digital Medicine, 4*(1), 132. https://doi.org/10.1038/s41746-021-00510-w